PMID- 35669685 OWN - NLM STAT- MEDLINE DCOM- 20220608 LR - 20231105 IS - 1664-2392 (Print) IS - 1664-2392 (Electronic) IS - 1664-2392 (Linking) VI - 13 DP - 2022 TI - High Normal Urinary Albumin-Creatinine Ratio Is Associated With Hypertension, Type 2 Diabetes Mellitus, HTN With T2DM, Dyslipidemia, and Cardiovascular Diseases in the Chinese Population: A Report From the REACTION Study. PG - 864562 LID - 10.3389/fendo.2022.864562 [doi] LID - 864562 AB - BACKGROUND: Albuminuria has been widely considered a risk factor for cardiovascular diseases (CVDs), which is associated with hypertension (HTN), type 2 diabetes mellitus (T2DM), HTN with T2DM, and dyslipidemia. However, the associations between albuminuria and HTN, T2DM, HTN with T2DM, dyslipidemia, and CVDs are still unclear. Thus, this study aimed to explore the association of albuminuria thoroughly, especially within the normal range, with the abovementioned diseases in the Chinese population. METHODS: This study included 40,188 participants aged over 40 years from seven centers across China. Urinary albumin-creatinine ratio (UACR) was firstly divided into the >/=30-mg/g group, indicating kidney damage, and <30-mg/g group. Furthermore, UACR was divided into five groups: the <20%, 20%-39%, 40%-59%, 60%-79%, and >/=80% groups, according to the quintile division of participants within the normal range. Propensity score matching was used to reduce bias, and multiple logistic regression models were conducted to examine the association between UACR and HTN, T2DM, HTN with T2DM, dyslipidemia, and CVDs. RESULTS: Multivariable regression analysis revealed that UACR, even within the normal range, is significantly associated with HTN, T2DM, HTN with T2DM, dyslipidemia, and CVDs, and the association between UACR and HTN with T2DM was the most significant in model 3 even after adjusting for confounding factors (HTN: OR = 1.56 (95% CI = 1.45-1.68), p < 0.0001; T2DM: OR = 1.78 (95% CI = 1.60-1.97), p < 0.0001; HTN with T2DM: OR = 1.76 (95% CI = 1.59-1.95), p < 0.0001; dyslipidemia: OR = 1.08 (95% CI = 1.01-1.14), p = 0.0146; CVDs: OR = 1.12 (95% CI = 1.00-1.25), p = 0.0475). In the stratified analysis, high normal UACR was significantly associated with HTN, T2DM, HTN with T2DM, and dyslipidemia in subgroups. CONCLUSIONS: In summary, we observe a higher prevalence of HTN, T2DM, HTN with T2DM, dyslipidemia, and CVDs in abnormal UACR and reveal a significant association of UACR, even within the normal range, with HTN, T2DM, HTN with T2DM, dyslipidemia, and CVDs. CI - Copyright (c) 2022 Wang, Wang, Li, Hu, Jin, Wang, Gao, Tang, Yan, Wan, Luo, Qin, Chen, Gu, Lyv and Mu. FAU - Wang, Jie AU - Wang J AD - Department of Endocrinology, The First Medical Center of PLA General Hospital, Beijing, China. AD - Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. FAU - Wang, Yun AU - Wang Y AD - Department of Endocrinology, The First Medical Center of PLA General Hospital, Beijing, China. AD - Graduate School, Chinese General Hospital, Beijing, China. FAU - Li, Yijun AU - Li Y AD - Department of Endocrinology, The First Medical Center of PLA General Hospital, Beijing, China. FAU - Hu, Ying AU - Hu Y AD - Department of Endocrinology, The First Medical Center of PLA General Hospital, Beijing, China. FAU - Jin, Lingzi AU - Jin L AD - Department of International Medical Services, Peking Union Medical College Hospital, Beijing, China. FAU - Wang, Weiqing AU - Wang W AD - Department of Endocrinology, Shanghai National Research Centre for Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. FAU - Gao, Zhengnan AU - Gao Z AD - Department of Endocrinology, Dalian Central Hospital, Dalian, China. FAU - Tang, Xulei AU - Tang X AD - First Hospital of Lanzhou University, Lanzhou, China. FAU - Yan, Li AU - Yan L AD - Department of Endocrinology, Sun Yat-Sen Memorial Hospital, Zhongshan University, Guangzhou, China. FAU - Wan, Qin AU - Wan Q AD - Department of Endocrinology, Southwest Medical University Affiliated Hospital, Luzhou, China. FAU - Luo, Zuojie AU - Luo Z AD - Department of Endocrinology, First Affiliated Hospital of Guangxi Medical University, Nanning, China. FAU - Qin, Guijun AU - Qin G AD - First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. FAU - Chen, Lulu AU - Chen L AD - Wuhan Union Hospital, Huazhong University of Science and Technology, Wuhan, China. FAU - Gu, Weijun AU - Gu W AD - Department of Endocrinology, The First Medical Center of PLA General Hospital, Beijing, China. AD - Graduate School, Chinese General Hospital, Beijing, China. FAU - Lyv, Zhaohui AU - Lyv Z AD - Department of Endocrinology, The First Medical Center of PLA General Hospital, Beijing, China. AD - Graduate School, Chinese General Hospital, Beijing, China. FAU - Mu, Yiming AU - Mu Y AD - Department of Endocrinology, The First Medical Center of PLA General Hospital, Beijing, China. AD - Graduate School, Chinese General Hospital, Beijing, China. LA - eng PT - Journal Article DEP - 20220520 PL - Switzerland TA - Front Endocrinol (Lausanne) JT - Frontiers in endocrinology JID - 101555782 RN - 0 (Albumins) RN - AYI8EX34EU (Creatinine) SB - IM MH - Aged MH - Albumins MH - Albuminuria/complications/etiology MH - *Cardiovascular Diseases/complications/etiology MH - China/epidemiology MH - Creatinine MH - *Diabetes Mellitus, Type 2/complications/epidemiology MH - *Dyslipidemias/complications/epidemiology MH - Humans MH - *Hypertension/complications/epidemiology PMC - PMC9165688 OTO - NOTNLM OT - cardiovascular diseases OT - diabetes OT - dyslipidemia OT - hypertension OT - urinary albumin-creatinine ratio COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/06/08 06:00 MHDA- 2022/06/09 06:00 PMCR- 2022/01/01 CRDT- 2022/06/07 02:42 PHST- 2022/01/28 00:00 [received] PHST- 2022/03/28 00:00 [accepted] PHST- 2022/06/07 02:42 [entrez] PHST- 2022/06/08 06:00 [pubmed] PHST- 2022/06/09 06:00 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fendo.2022.864562 [doi] PST - epublish SO - Front Endocrinol (Lausanne). 2022 May 20;13:864562. doi: 10.3389/fendo.2022.864562. eCollection 2022.